Pernix Therapeutics Holdings, Inc
) recently completed its previously announced acquisition of
Somaxon Pharmaceuticals for $25 million. The acquisition was
announced on Dec 11, 2012.
As per the terms of the agreement, the stockholders of Somaxon
will receive approximately 3,665,689 shares of Pernix common
stock at a price of $6.82 per share.
With this acquisition, Pernix now has insomnia drug, Silenor,
in its portfolio. Pernix will promote Silenor and might also
develop Silenor as an over-the-counter (OTC) product.
Silenor generated sales of $11.7 million as of Sep 30, 2012 on
a trailing 12-month basis. Pernix expects net sales from Silenor
on an annualized basis to come between $10 million and $15
We remind investors that Pernix has been quite active on the
acquisition front with the acquisitions of Cypress
Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals in Jan
The erstwhile Cypress Pharma offered generic drugs targeting
the fields of cough and cold, nutritional supplements,
analgesics, urinary tract, women's health, pre-natal vitamins and
dental health. On the other hand, Hawthorn Pharma offered branded
pharmaceutical products for allergy, respiratory, iron
deficiency, nephrology and pain management.
Hence, the acquisitions will widen Pernix's portfolio in the
respective areas. Pernix currently markets generic products
through its wholly-owned subsidiary, Macoven Pharmaceuticals.
We remain cautious on the successful integration of the
acquisitions by Pernix given the change in top management. As
announced on Jan 24, 2013, the Chief Financial Officer (CFO)
David Becker will step down effective Mar 31, 2013 due to
personal reasons. The search for a new CFO is underway.
Pernix Therapeutics currently carries a Zacks Rank #2 (Buy).
Other pharma stocks, which also appear to be attractive, include
). All three carry a Zacks Rank #2.
AVANIR PHARM (AVNR): Free Stock Analysis
FURIEX PHARMACT (FURX): Free Stock Analysis
PERNIX THERAPTC (PTX): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.